how do glp-1 medications work and Anesthesia: Considerations and Cautions for CRNAs You've probably heard a lot

Description

While on adjuvant chemo and hormonal therapy, her weight increased dramatically and peaked 4 years later to 66.3 kg (16.4 kg weight gain) and a BMI of 24.9

talk to your healthcare provider about what is right for you

Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial

The cardiovascular safety profiles of GLP-1RAs are favorable, with no significant increase in the incidence of acute pancreatitis or pancreatic cancer reported.14 However, their use is associated with a higher frequency of gastrointestinal adverse events, such as nausea, vomiting, and diarrhea.15 GLP-1RAs are considered safe in patients with chronic kidney disease and effective in reducing the risk of severe hypoglycemia.16 In individuals with established cardiovascular diseases, GLP-1RAs have been shown to significantly lower the risk of major adverse cardiovascular events.15 Nevertheless, limited cardiovascular and renal outcome data for certain agents, such as oral semaglutide, have constrained their broader clinical application.17 In the context of post-transplant diabetes, GLP-1RAs exhibit efficacy and safety profiles comparable to those observed in non-transplant populations.18 This review was conducted through comprehensive searches of electronic databases, including Web of Science and PubMed, using a full-text search strategy

This allows your provider to select the ideal compound and starting dose upfront, increasing the likelihood of rapid, sustained weight loss and better tolerability